CA2608751A1 - Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling - Google Patents

Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling Download PDF

Info

Publication number
CA2608751A1
CA2608751A1 CA002608751A CA2608751A CA2608751A1 CA 2608751 A1 CA2608751 A1 CA 2608751A1 CA 002608751 A CA002608751 A CA 002608751A CA 2608751 A CA2608751 A CA 2608751A CA 2608751 A1 CA2608751 A1 CA 2608751A1
Authority
CA
Canada
Prior art keywords
seq
monoclonal antibody
sequence shown
cell
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002608751A
Other languages
English (en)
French (fr)
Inventor
Sharon Lea Aukerman
Bahija Jallal
Mohammad Luqman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Xoma Technology Ltd USA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2608751A1 publication Critical patent/CA2608751A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
CA002608751A 2005-05-18 2006-05-18 Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling Abandoned CA2608751A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68258205P 2005-05-18 2005-05-18
US60/682,582 2005-05-18
US74928505P 2005-12-09 2005-12-09
US60/749,285 2005-12-09
PCT/US2006/019414 WO2006125143A2 (en) 2005-05-18 2006-05-18 Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling

Publications (1)

Publication Number Publication Date
CA2608751A1 true CA2608751A1 (en) 2006-11-23

Family

ID=37022828

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002608751A Abandoned CA2608751A1 (en) 2005-05-18 2006-05-18 Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling

Country Status (6)

Country Link
US (2) US8337851B2 (enExample)
EP (1) EP1894012A2 (enExample)
JP (2) JP5208730B2 (enExample)
AU (1) AU2006247067B2 (enExample)
CA (1) CA2608751A1 (enExample)
WO (1) WO2006125143A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1894012A2 (en) * 2005-05-18 2008-03-05 Novartis AG Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
ES2444465T5 (es) 2005-12-09 2023-11-30 Academisch Medisch Centrum Bij De Univ Van Amsterdam Medios y procedimientos para influenciar la estabilidad de las células productoras de anticuerpos
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
US20090075272A1 (en) * 2006-01-20 2009-03-19 Hollmann C Annette Method to Identify CD40-Sensitive Cells Using Gene Expression
NZ571757A (en) 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
DE602006004196D1 (de) * 2006-06-01 2009-01-22 Cellzome Ag Verfahren zur Identifizierung von mit ZAP-70 wechselwirkenden Molekülen und zur ZAP-70-Reinigung
CA2704499C (en) * 2007-11-07 2020-03-10 Genentech, Inc. Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
CN102459639A (zh) 2009-04-18 2012-05-16 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法
WO2010127186A1 (en) 2009-04-30 2010-11-04 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
WO2011008093A1 (en) 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
US20110064747A1 (en) * 2009-08-25 2011-03-17 Rangaprasad Sarangarajan Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)
SI2556171T1 (sl) 2010-04-05 2016-03-31 Prognosys Biosciences, Inc. Prostorsko kodirane biološke analize
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US9766249B2 (en) * 2010-04-19 2017-09-19 Biomarker Strategies, Llc Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
NZ611600A (en) 2010-12-02 2015-02-27 Aimm Therapeutics Bv Means and methods for producing high affinity antibodies
WO2012139110A2 (en) 2011-04-08 2012-10-11 Prognosys Biosciences, Inc. Peptide constructs and assay systems
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
US8778345B2 (en) 2011-04-29 2014-07-15 Apexigen, Inc. Anti-CD40 antibodies
EP3901280B1 (en) 2012-10-17 2025-03-12 10x Genomics Sweden AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
WO2014070934A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
US11231419B2 (en) 2013-03-15 2022-01-25 Prognosys Biosciences, Inc. Methods for detecting peptide/MHC/TCR binding
CN105849275B (zh) 2013-06-25 2020-03-17 普罗格诺西斯生物科学公司 检测样品中生物靶标的空间分布的方法和系统
WO2015070037A2 (en) 2013-11-08 2015-05-14 Prognosys Biosciences, Inc. Polynucleotide conjugates and methods for analyte detection
WO2015085171A1 (en) * 2013-12-06 2015-06-11 Adventist Health Systems/Sunbelt, Inc. Role of mcp-1 in relapse of acute myeloid leukemia after hematopoietic stem cell transplantation
AU2015211480B2 (en) 2014-01-31 2020-05-14 Kling Biotherapeutics B.V. Means and methods for producing stable antibodies
EP3210142B1 (en) * 2014-10-24 2020-09-16 Koninklijke Philips N.V. Assessment of tgf-cellular signaling pathway activity using mathematical modelling of target gene expression
CA2982146A1 (en) 2015-04-10 2016-10-13 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US20170038387A1 (en) * 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
ES2885476T3 (es) * 2015-10-05 2021-12-13 Ucb Biopharma Sprl Firmas moleculares para uso en diagnóstico y análisis de respuesta al tratamiento de enfermedades autoinmunes
DK3529611T3 (da) * 2016-10-23 2023-02-06 Berkeley Lights Inc Fremgangsmåder til screening af b-cellelymfocytter
CN112639474A (zh) * 2018-05-14 2021-04-09 卑尔根生物股份公司 血清生物标志物
US20210251994A1 (en) 2018-06-15 2021-08-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
EP3976820A1 (en) 2019-05-30 2022-04-06 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
WO2021236929A1 (en) 2020-05-22 2021-11-25 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
EP4025692A2 (en) 2020-06-02 2022-07-13 10X Genomics, Inc. Nucleic acid library methods
CN116249785A (zh) 2020-06-02 2023-06-09 10X基因组学有限公司 用于抗原-受体的空间转录组学
ES2981265T3 (es) 2020-06-08 2024-10-08 10X Genomics Inc Métodos para determinar un margen quirúrgico y métodos de uso del mismo
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CN113684180B (zh) * 2021-08-31 2023-05-26 山东大学第二医院 一种提高骨髓瘤杀伤活性的nk细胞制备方法
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
CN115845063B (zh) * 2022-12-20 2024-07-09 中国医学科学院医学生物学研究所 与急性t淋巴细胞白血病治疗相关的靶点cd40lg及其应用
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024173352A2 (en) * 2023-02-13 2024-08-22 Shattuck Labs, Inc. Methods of treating cancer with a sirp1a-based chimeric protein

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2330916C (en) * 1998-05-19 2011-04-05 Research Development Foundation Triterpene compositions and methods for use thereof
EP1286692A4 (en) * 2000-04-25 2004-11-17 Idec Pharma Corp INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR THE TREATMENT OF LYMPHOMAS OF THE CENTRAL NERVOUS SYSTEM
CA2424296A1 (en) * 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20070254850A1 (en) * 2002-10-30 2007-11-01 Judy Lieberman Methods for Treating and Preventing Apoptosis-Related Diseases Using Rna Interfering Agents
EP1570273B1 (en) * 2002-12-11 2018-05-30 Ventana Medical Systems, Inc. Method for predicting the response to her2-directed therapy
GB0301566D0 (en) * 2003-01-23 2003-02-26 Eirx Therapeutics Ltd Kinasaes and GPCRs involved in apoptosis
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
EP1694360B1 (en) * 2003-11-04 2010-08-04 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
US20070098718A1 (en) * 2003-11-04 2007-05-03 Chiron Methods of therapy for b cell-related cancers
EP1718602A4 (en) * 2004-01-30 2007-12-12 Peplin Biolipids Pty Ltd THERAPEUTIC AND CARRIER MOLECULES
US20070292439A1 (en) * 2004-04-27 2007-12-20 Novartis Vaccines And Diagnostics, Inc. Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
EP1894012A2 (en) * 2005-05-18 2008-03-05 Novartis AG Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling

Also Published As

Publication number Publication date
US20090041773A1 (en) 2009-02-12
WO2006125143A2 (en) 2006-11-23
EP1894012A2 (en) 2008-03-05
AU2006247067A1 (en) 2006-11-23
JP2008539794A (ja) 2008-11-20
US8337851B2 (en) 2012-12-25
JP2013057686A (ja) 2013-03-28
JP5208730B2 (ja) 2013-06-12
US20130230528A1 (en) 2013-09-05
AU2006247067B2 (en) 2012-06-07
WO2006125143A3 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
AU2006247067B2 (en) Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
US8333970B2 (en) Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject having an inflammatory or autoimmune disease
US10647771B2 (en) Antibody that binds to human programmed death ligand 2 (PD-L2) and uses thereof
AU2014339900B2 (en) Anti-PD-L1 monoclonal antibodies and fragments thereof
AU2009239437B2 (en) Levels of BCMA protein expression on B cells and use in diagnostic methods
AU2006308606C1 (en) Uses of anti-CD40 antibodies
US20230331847A1 (en) Anti-phosphotyrosinylated programmed death 1 (pd-1) monoclonal antibodies, methods of making and methods of using thereof
CN102978277A (zh) 使用生物标志的测定法和方法
CA2741489A1 (en) Methods, compositions, and kits for diagnosing, monitoring, and treating disease
CN118994395A (zh) Vista受体
HK1110942B (en) Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
WO2023144303A1 (en) Cd38 as a biomarker and biotarget in t-cell lymphomas

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20161107